The Northwest Clinical Community Oncology Program (NW CCOP) has been in existence since the inception of the National Cancer Institute's Clinical Community Oncology Program. As one of the founding CCOPs, the NW CCOP plays an integral role in achieving the National Cancer Institute's (NCI) objective of connecting community cancer specialists and primary care providers with NCI sponsored clinical trials. The NW CCOP is an experienced consortium of hospitals and independent oncology practices spanning three states serving local communities within western Washington, northern Oregon and northern Idaho. The overall purpose of the NW CCOP is to bring clinical advances through the most cutting edge research protocols to local communities. NW CCOP utilizes the Clinical Trials Support Unit (CTSU) as well as the Southwest Oncology Group (SWOG), National Surgical Adjuvant Breast and Bowel Project (NSABP), University of Rochester Cancer Center (URCC), M.D. Anderson Cancer Center (MDACC), and the Sun Coast CCOP Research Bases. The NW CCOP provides community oncologists with the opportunity to participate in a variety of treatment and cancer prevention and control research trials provided by these research bases.
The specific aims of the NW CCOP are to: increase patients'access within Washington, Idaho, and Oregon to advances in treatment and cancer control and prevention clinical trials within their local communities;Expand outreach efforts to minority and underserved populations;Increase the knowledge, awareness, and involvement of the primary healthcare providers to promote increased participation in cancer treatment, and cancer control and prevention trials;and Provide enhanced systems supporting the consortium through communication and training among providers and coordinators thereby promoting quality and timely data collection while maintaining a level of excellence in protection of study participants.

Public Health Relevance

For the past three decades, the NW CCOP has contributed to the body of knowledge and advancements of cancer treatments. The NW CCOP continues to supports the investigation of a variety of chemotherapy agents, from being investigational agents to FDA approved products for a host of indications. Since 1983, we have contributed to significant medical advances especially in the adjuvant treatment settings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035281-29
Application #
8307610
Study Section
Special Emphasis Panel (ZCA1-SRLB-E (J1))
Program Officer
Whitman, Cynthia B
Project Start
1983-09-15
Project End
2015-05-31
Budget Start
2012-09-06
Budget End
2013-05-31
Support Year
29
Fiscal Year
2012
Total Cost
$596,302
Indirect Cost
$96,834
Name
Tacoma General Hospital
Department
Type
DUNS #
151474301
City
Tacoma
State
WA
Country
United States
Zip Code
98405
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900
Stiff, Patrick J; Unger, Joseph M; Cook, James R et al. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369:1681-90
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25

Showing the most recent 10 out of 93 publications